Isotretinoin is a Safety Therapy on Kidney: A Retrospective Study

Objective: Isotretinoin is widely used in severe acne treatment. The drug leads to several adverse effects; skin and mucous membranes are frequently affected. It may also cause serious and fatal adverse effects like kidney damage. The aim of this study is to determine the safety of isotretinoin usage on kidney functions in patients with acne vulgaris. Methods: Eighty six patients with severe acne vulgaris and receiving 0.5 mg/kg/day of isotretinoin treatment were included in the study and evaluated retrospectively. Serum urea, creatinine, complete blood count, aspartate aminotransferase, alanine aminotransferase, lipid profile datas were obtained from patient files. Glomerular filtration rate (GFR) was measured at the baseline of treatment, 3rd and 6th months of treatment. Results: We detected significant increases in levels of creatinine on the third month (p=0.041), but it was not clinically significant, and there was no significant difference in creatinine levels at 6th month. There were no significant differences among the baseline, 3rd month (p=0.066) and 6th month (p=0.429) of GFR values. Conclusion: We think that isotretinoin is safe for the kidneys but patients with high creatinine levels at the baseline of treatment should be closely followed up.

[1]  A. Metin,et al.  The weeks and the cumulative doses of the first adverse events related to oral isotretinoin in acne patients: analysis of 300 patients , 2017, The Journal of dermatological treatment.

[2]  B. Melnik Apoptosis May Explain the Pharmacological Mode of Action and Adverse Effects of Isotretinoin, Including Teratogenicity. , 2017, Acta dermato-venereologica.

[3]  B. Miziołek,et al.  The safety of isotretinoin in patients with lupus nephritis: a comprehensive review , 2017, Cutaneous and ocular toxicology.

[4]  Demet Kartal,et al.  The frequency of hematuria in acne vulgaris patients during isotretinoin treatment , 2017, Cutaneous and ocular toxicology.

[5]  Y. Solak,et al.  Isotretinoin use for acne vulgaris is associated with increased serum uric acid levels , 2017, The Journal of dermatological treatment.

[6]  G. Kaya Aksoy,et al.  Eosinophilic tubulointerstitial nephritis on treatment with isotretinoin , 2016, European Journal of Pediatrics.

[7]  J. Kirby,et al.  Standardized laboratory monitoring with use of isotretinoin in acne. , 2016, Journal of the American Academy of Dermatology.

[8]  J. Leyden,et al.  Guidelines of care for the management of acne vulgaris. , 2016, Journal of the American Academy of Dermatology.

[9]  B. Cho,et al.  A Case of Cyclosporine-Induced Sebaceous Hyperplasia in a Renal Transplant Patient Successfully Treated with Isotretinoin , 2016, Annals of dermatology.

[10]  E. Siew,et al.  Choice of Reference Serum Creatinine in Defining Acute Kidney Injury , 2015, Nephron.

[11]  A. Turhanoğlu,et al.  Isotretinoin treatment in patients with acne vulgaris: does it impact muscle strength, fatigue, and endurance? , 2015, Cutis (New York, N.Y.).

[12]  A. Bello,et al.  Canadian Society of Nephrology commentary on the KDIGO clinical practice guideline for CKD evaluation and management. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  Shinjita Das,et al.  Recent Advances in Acne Pathogenesis: Implications for Therapy , 2014, American Journal of Clinical Dermatology.

[14]  Y. Çayır,et al.  Effects of oral isotretinoin on lipids and liver enzymes in acne patients. , 2014, Cutis.

[15]  A. Bowirrat,et al.  Acute kidney injury following isotretinoin treatment , 2013, The American journal of case reports.

[16]  E. Sarıfakıoğlu,et al.  Terminal Hematuria Associated with Oral Isotretinoin Treatment in a Patient with Acne Vulgaris , 2012, Pediatric dermatology.

[17]  S. Ritz‐Timme,et al.  Severe generalised rhabdomyolysis with fatal outcome associated with isotretinoin , 2012, International Journal of Legal Medicine.

[18]  M. Goh,et al.  Successful treatment of cyclosporine‐induced sebaceous hyperplasia with oral isotretinoin in two renal transplant recipients , 2011, The Australasian journal of dermatology.

[19]  Jens-Peter Schenk,et al.  13-cis Retinoic Acid Treatment of a Patient With Chemotherapy Refractory Nephroblastomatosis , 2009, Journal of pediatric hematology/oncology.

[20]  Y. Kaymak Creatine phosphokinase values during isotretinoin treatment for acne , 2008, International journal of dermatology.

[21]  M. Zeier,et al.  Chronic low-dose isotretinoin treatment limits renal damage in subtotally nephrectomized rats , 2008, Journal of Molecular Medicine.

[22]  İ. Ertam,et al.  Is it necessary to have routine blood tests in patients treated with isotretinoin? , 2006, The Journal of dermatological treatment.

[23]  N. Gretz,et al.  13-cis retinoic acid inhibits development and progression of chronic allograft nephropathy. , 2005, The American journal of pathology.

[24]  H. Kawachi,et al.  Retinoic acid receptor α and retinoid X receptor specific agonists reduce renal injury in established chronic glomerulonephritis of the rat , 2004, Journal of Molecular Medicine.

[25]  E. Ritz,et al.  Retinoid agonist isotretinoin ameliorates obstructive renal injury. , 2003, The Journal of urology.

[26]  É. Kiss,et al.  Isotretinoin ameliorates renal damage in experimental acute renal allograft rejection1 , 2003, Transplantation.

[27]  J. Bressieux,et al.  [Value of isotretinoin in the treatment of acne in hemodialysis patients: apropos of 1 case]. , 2003, Nephrologie.

[28]  E. Ritz,et al.  Retinoid receptor-specific agonists alleviate experimental glomerulonephritis. , 2002, American journal of physiology. Renal physiology.

[29]  Y. Nevo,et al.  Clinical significance of markedly elevated serum creatine kinase levels in patients with acne on isotretinoin. , 2001, Acta dermato-venereologica.

[30]  J. V. van Oers,et al.  Nephrotic syndrome associated with isotretinoin. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.